Loading...

PHAT PHATHOM PHARMACEUTICALS INC Management Changes 8-K Filing

PHTH

PHT

PHATHOM PHARMACEUTICALS INC

(PHAT)

2025 8-K

Show Summary

Show Summary

Other Special Situation

Pre-Market Approval

Financial Statements

Director Appointment

Financial Results

Earnings Report

Financial Results

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Other Special Situation

Bylaws Amendment

Loan Agreement Amendment

FDA Acceptance of New Drug ...

Financial Results Announcement

FDA Approval for VOQUEZNA T...

FDA Stability Data Submission

Financial Results Announcement

Stock Option Exchange

Stock Option Exchange

FDA Acknowledges NDA Resubm...

Annual Meeting and Changes ...

Underwriting Agreement

Resubmission of New Drug Ap...

Financial Results Announcement

Regulatory Update

Financial Results Announcement

Positive Study Results for ...

External Links:

Phathom Pharmaceuticals appointed Theodore R. Schroeder as a Class I director effective April 16, 2025, with a term expiring at the 2026 annual meeting, and he will receive stock options and RSUs as part of his compensation.

AI Assistant

PHATHOM PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.